Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTN3A1 | O00481 | 3/20 | 0.36 |
| ▸ | PPARA | Q07869 | 5/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | CETP | P11597 | 3/20 | 0.32 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.32 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.32 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | PPARG | P37231 | 3/20 | 0.31 |
| ▸ | EGFR | P00533 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31480647 | 0.93 | BTN3A1 (0.37) | BTN3A1PPARATSHRCETPSMN1; SMN2 | |
| SCHEMBL31480692 | 0.87 | BTN3A1 (0.36) | BTN3A1PPARATSHRCETPFOLH1 | |
| SCHEMBL31480857 | 0.80 | BTN3A1 (0.37) | BTN3A1TSHRCETP | |
| SCHEMBL31480733 | 0.78 | ALDH1A1 (0.36) | TSHRCETPHDAC3HDAC1HDAC2 | |
| SCHEMBL31480985 | 0.76 | ALDH1A1 (0.36) | BTN3A1PPARASMN1; SMN2EGFR | |
| SCHEMBL8791230 | 0.74 | TSHR (0.38) | BTN3A1TSHRCETPFOLH1 | |
| SCHEMBL23328083 | 0.70 | TSHR (0.42) | BTN3A1TSHRCETPFOLH1 | |
| SCHEMBL2751224 | 0.69 | TSHR (0.41) | BTN3A1TSHRCETPFOLH1 | |
| SCHEMBL10378803 | 0.69 | ALDH1A1 (0.49) | BTN3A1TSHRCETPFOLH1 | |
| SCHEMBL21189481 | 0.69 | ALDH1A1 (0.49) | BTN3A1TSHRCETPFOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250120989-A1 | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. | 2025-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250120989-A1 | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND USES THEREOF | SDHA, SDHB, DPYD | BTN3A1 4478/4885PPARA 1888/4885TSHR 4706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.